TIGERMED Schedules 28 Aug 2026 Board Meeting to Approve H1 2026 Results and Possible Interim Dividend

Bulletin Express

08/18

Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has announced that its board of directors will convene on 28 August 2026. The agenda includes:

• Reviewing and approving the unaudited interim results for the six months ended 30 June 2026. • Considering the declaration and payment of an interim dividend, if applicable.

The notification was released on 18 August 2026 under the signature of Chairman Ye Xiaoping. TIGERMED’s current board comprises three executive directors (Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu), one employee director (Mr. Wu Hao) and three independent non-executive directors (Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu Paul Yu Hay).

Market participants will receive the company’s interim performance update and any dividend decision following the board meeting.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1117168289"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1117168289\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1117168289?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-18 17:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117168289","market":"hk","top_or_hot":-1,"title":"TIGERMED Schedules 28 Aug 2026 Board Meeting to Approve H1 2026 Results and Possible Interim Dividend","media":"Bulletin Express","content":"<p>Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has announced that its board of directors will convene on 28 August 2026. The agenda includes:</p>\n<p>• Reviewing and approving the unaudited interim results for the six months ended 30 June 2026.  \n• Considering the declaration and payment of an interim dividend, if applicable.</p>\n<p>The notification was released on 18 August 2026 under the signature of Chairman Ye Xiaoping. TIGERMED’s current board comprises three executive directors (Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu), one employee director (Mr. Wu Hao) and three independent non-executive directors (Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu Paul Yu Hay).</p>\n<p>Market participants will receive the company’s interim performance update and any dividend decision following the board meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TIGERMED Schedules 28 Aug 2026 Board Meeting to Approve H1 2026 Results and Possible Interim Dividend</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTIGERMED Schedules 28 Aug 2026 Board Meeting to Approve H1 2026 Results and Possible Interim Dividend\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2026-08-18 17:45</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has announced that its board of directors will convene on 28 August 2026. The agenda includes:</p>\n<p>• Reviewing and approving the unaudited interim results for the six months ended 30 June 2026.  \n• Considering the declaration and payment of an interim dividend, if applicable.</p>\n<p>The notification was released on 18 August 2026 under the signature of Chairman Ye Xiaoping. TIGERMED’s current board comprises three executive directors (Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu), one employee director (Mr. Wu Hao) and three independent non-executive directors (Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu Paul Yu Hay).</p>\n<p>Market participants will receive the company’s interim performance update and any dividend decision following the board meeting.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03347","symbol_name":"泰格醫藥","start_time":0,"source_url":"","article_id":"1117168289","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117168289","pubTimestamp":1787046317,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has announced that its board of directors will convene on 28 August 2026. The agenda includes: • Reviewing and approving the unaudited interim...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03347":"泰格医药"},"translate_title":"泰格医药定于 2026 年 8 月 28 日召开董事会会议，批准 2026 年上半年业绩和可能的中期股息","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03347":1},"content_text":"Hangzhou Tigermed Consulting Co., Ltd. (TIGERMED) has announced that its board of directors will convene on 28 August 2026. The agenda includes:\n• Reviewing and approving the unaudited interim results for the six months ended 30 June 2026.  \n• Considering the declaration and payment of an interim dividend, if applicable.\nThe notification was released on 18 August 2026 under the signature of Chairman Ye Xiaoping. TIGERMED’s current board comprises three executive directors (Dr. Ye Xiaoping, Ms. Cao Xiaochun and Mr. Wen Zengyu), one employee director (Mr. Wu Hao) and three independent non-executive directors (Mr. Yuan Huagang, Ms. Liu Yuwen and Mr. Siu Paul Yu Hay).\nMarket participants will receive the company’s interim performance update and any dividend decision following the board meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}